DE69332566D1 - Impfstoff enthaltend lebendes virus - Google Patents

Impfstoff enthaltend lebendes virus

Info

Publication number
DE69332566D1
DE69332566D1 DE69332566T DE69332566T DE69332566D1 DE 69332566 D1 DE69332566 D1 DE 69332566D1 DE 69332566 T DE69332566 T DE 69332566T DE 69332566 T DE69332566 T DE 69332566T DE 69332566 D1 DE69332566 D1 DE 69332566D1
Authority
DE
Germany
Prior art keywords
virus
avian
human
lyophilization
purifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332566T
Other languages
English (en)
Other versions
DE69332566T2 (de
Inventor
Laszlo K Csatary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNITED CANCER RES INST ALEXAND
Original Assignee
UNITED CANCER RES INST ALEXAND
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU9200966A external-priority patent/HU207297B/hu
Application filed by UNITED CANCER RES INST ALEXAND filed Critical UNITED CANCER RES INST ALEXAND
Application granted granted Critical
Publication of DE69332566D1 publication Critical patent/DE69332566D1/de
Publication of DE69332566T2 publication Critical patent/DE69332566T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69332566T 1992-03-24 1993-03-23 Impfstoff enthaltend lebendes virus Expired - Fee Related DE69332566T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9200966A HU207297B (en) 1992-03-24 1992-03-24 Process for producing 4-hydroxy-7-chloro-quinoline
HU9226547 1992-08-17
PCT/US1993/002441 WO1993018790A1 (en) 1992-03-24 1993-03-23 Vaccine containing live virus for therapy of viral diseases and malignancies

Publications (2)

Publication Number Publication Date
DE69332566D1 true DE69332566D1 (de) 2003-01-23
DE69332566T2 DE69332566T2 (de) 2003-09-04

Family

ID=26318074

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332566T Expired - Fee Related DE69332566T2 (de) 1992-03-24 1993-03-23 Impfstoff enthaltend lebendes virus

Country Status (10)

Country Link
EP (1) EP0713397B1 (de)
KR (1) KR950700756A (de)
AT (1) ATE229344T1 (de)
AU (1) AU673827B2 (de)
CA (1) CA2132328C (de)
DE (1) DE69332566T2 (de)
DK (1) DK0713397T3 (de)
ES (1) ES2188593T3 (de)
PT (1) PT713397E (de)
WO (1) WO1993018790A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435118D1 (de) 1993-04-30 2008-08-28 Wellstat Biologics Corp Gereinigte Zusammensetzungen von Newcastle-Krankheitvirus
DE4422238C2 (de) * 1994-06-24 1996-05-30 Behringwerke Ag Verfahren zur Isolierung einer Antigenpräparation
EP0968284B1 (de) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
GB9808922D0 (en) 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DK1133316T3 (da) * 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
EP1390046A4 (de) 1999-04-15 2005-04-20 Wellstat Biologics Corp Behandlung von neoplasmen mit viren
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
CA2386920C (en) 1999-09-17 2012-01-24 Pro-Virus, Inc. Oncolytic virus
WO2005066333A1 (en) * 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
EP1708747A2 (de) 2004-01-15 2006-10-11 Intervet International BV Stabilisatoren nichttierischen ursprungs und herstellungsverfahren dafür
JP2008518632A (ja) 2004-11-03 2008-06-05 イントロゲン セラピューティックス， インコーポレイテッド アデノウイルスベクターの製造および精製のための新規方法
CA2616943C (en) 2005-07-29 2016-04-12 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2327764B1 (de) 2009-11-30 2011-12-28 United Cancer Research Institute Neuer Klon des Geflügelpestvirus, Herstellung und Anwendung bei der medizinischen Behandlung von Krebs
EA201390810A1 (ru) 2010-12-02 2013-09-30 Онколитикс Байотек Инк. Жидкие вирусные составы
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
WO2023191628A1 (en) * 2022-03-30 2023-10-05 Bioneedle Drug Delivery B.V. A process for storing biologically active constructs in a biodegradable material

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US3874999A (en) * 1973-10-31 1975-04-01 American Cyanamid Co Process for the purification of virus vaccine
BE853923A (fr) * 1977-04-25 1977-10-25 Rit Rech Ind Therapeut Nouveau vaccin vivant ameliore contre le pseudopeste aviaire et son procede de preparation
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
HU197846B (en) * 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
DD229031A1 (de) * 1984-11-19 1985-10-30 Fi Fuer Lungenkrankheiten Und Verfahren zur herstellung eines oral-impfstoffes
JP2559783B2 (ja) * 1986-08-04 1996-12-04 アメリカ合衆国 ヒトｂ親リンパ性ウイルス（ｈｂｌｖ）の単離及び生成物
US4824668A (en) * 1987-03-09 1989-04-25 Sterwin Laboratories Inc. Attenuated infectious bursal disease virus strain and vaccine therefrom
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
ATE211168T1 (de) * 1990-05-21 2002-01-15 Univ Tulane Assoziation zwischen einem menschlichen immunschwäche-virus verwandten retrovirus und dem sjoegren-syndrom

Also Published As

Publication number Publication date
DE69332566T2 (de) 2003-09-04
CA2132328A1 (en) 1993-09-30
AU673827B2 (en) 1996-11-28
WO1993018790A1 (en) 1993-09-30
EP0713397A4 (de) 1995-12-07
CA2132328C (en) 2000-10-31
EP0713397A1 (de) 1996-05-29
DK0713397T3 (da) 2003-03-31
ES2188593T3 (es) 2003-07-01
ATE229344T1 (de) 2002-12-15
EP0713397B1 (de) 2002-12-11
KR950700756A (ko) 1995-02-20
AU3922293A (en) 1993-10-21
PT713397E (pt) 2003-04-30

Similar Documents

Publication Publication Date Title
DE69332566D1 (de) Impfstoff enthaltend lebendes virus
CA1331444C (en) Ibdv production in continuous lines
Silva et al. Effects of hydrostatic pressure on a membrane-enveloped virus: high immunogenicity of the pressure-inactivated virus
BR9908424A (pt) Processo para purificar uma preparação de herpesvìrus
DE68915165D1 (de) Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
US4317811A (en) Herpes simplex type 1 subunit vaccine
DE3689622T2 (de) Impfstoffe gegen menschliche respiratorische viren.
IL128804A (en) Method for preparing live virus, live chimeric virus obtained by method and vaccine containing the virus
CN103333242A (zh) scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
IE46463B1 (en) Novel vaccine and its preparation
Budowsky et al. Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of β-propiolactone
US4946676A (en) Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide
Cox The structural proteins of rabies virus
DZ1550A1 (fr) Vaccin depourvu de cellules contre le virus de la maladie marek.
Galabov [28] Induction and characterization of tortoise interferon
RU2142816C1 (ru) Способ получения антигерпетической вакцины и лекарственная форма на ее основе
Carmichael et al. Small-plaque variant of canine herpesvirus with reduced pathogenicity for newborn pups
Gillespie et al. The Prophylactic Effects of E. coli‐Derived Bovine Interferon AlphaI1 on Bovine Virus Diarrhoea Virus Disease in Calves after Intramuscular Administration
DK257887D0 (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
RU2195959C1 (ru) Инактивированная вакцина против синдрома гидроперикардита кур
PAYNE STUDIES ON ACUTE AND LATENT HERPES SIMPLEX VIRUS TYPE 1 INFECTIONS AND THE INFLUENCE OF SERUM IMMUNOGLOBULINS.
Glück et al. New aspects concerning the immunogenicity of rabies vaccines produced in animal brains (duck embryo)
Stinski et al. Distribution of arbovirus antigens in density gradients
Grabowska et al. A sensitive method for NDV isolation using media modified by 5-iodo-2-deoxyuridine(IDU).
Xiaobin et al. Analysis of the Antigens of Detergent Disrupted Bovine Ephemeral Fever Virus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee